Lestaurtinib Completed Phase 2 Trials for Agnogenic Myeloid Metaplasia / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00494585CEP-701 for PH-negative Myelofibrosis